These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 29157068)

  • 21. Safety and Immunogenicity of an Egg-Cultivated Quadrivalent Inactivated Split-virion Influenza Vaccine (GC3110A) in Healthy Korean Children: a Randomized, Double-blinded, Active-controlled Phase III Study.
    Lee J; Lee KY; Kim JH; Kim CS; Eun BW; Kim HM; Kim DH; Hong YJ; Choi YY; Jo DS; Ma SH; Kang JH
    J Korean Med Sci; 2018 Mar; 33(13):e100. PubMed ID: 29573247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
    Tsurudome Y; Kimachi K; Okada Y; Matsuura K; Ooyama Y; Ibaragi K; Kino Y; Ueda K
    Microbiol Immunol; 2015 Oct; 59(10):597-604. PubMed ID: 26272602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and safety of inactivated influenza virus vaccine in young children in 2003-2004.
    Mitchell DK; Ruben FL; Gravenstein S
    Pediatr Infect Dis J; 2005 Oct; 24(10):925-7. PubMed ID: 16220095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and safety of an intramuscular split-virion quadrivalent inactivated influenza vaccine in individuals aged ≥ 6 months in India.
    Agarkhedkar S; Chhatwal J; Kompithra RZ; Lalwani SK; Narayan A; Muninarayanaswam V; Gogtay N; Dotter K; Gresset-Bourgeois V
    Hum Vaccin Immunother; 2019; 15(4):973-977. PubMed ID: 30762467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quadrivalent influenza vaccine (Sinovac Biotech) for seasonal influenza prophylaxis.
    Tao YY; Li JX; Hu YM; Hu YS; Zeng G; Zhu FC
    Expert Rev Vaccines; 2021 Jan; 20(1):1-11. PubMed ID: 33434084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.
    Choi WS; Noh JY; Song JY; Cheong HJ; Wie SH; Lee JS; Lee J; Kim SW; Jeong HW; Jung SI; Kim YS; Woo HJ; Kim KH; Kim H; Kim WJ
    Hum Vaccin Immunother; 2017 Jul; 13(7):1653-1660. PubMed ID: 28406746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Immunogenicity of inacitivated quadrivalent influenza vaccine in adults aged 18-64 years: A systematic review and Meta-analysis].
    Meng ZY; Zhang JY; Zhang ZG; Luo D; Yang XM
    Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Dec; 39(12):1636-1641. PubMed ID: 30572392
    [No Abstract]   [Full Text] [Related]  

  • 28. Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18-49 Years of Age.
    Dunkle LM; Izikson R; Patriarca PA; Goldenthal KL; Muse D; Cox MMJ
    J Infect Dis; 2017 Dec; 216(10):1219-1226. PubMed ID: 28968871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50years of age: Results from a phase III, randomized, non-inferiority trial.
    Ofori-Anyinam O; Leroux-Roels G; Drame M; Aerssens A; Maes C; Amanullah A; Schuind A; Li P; Jain VK; Innis BL
    Vaccine; 2017 Nov; 35(46):6321-6328. PubMed ID: 28987445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial.
    Chen H; Huang Z; Chang S; Hu M; Lu Q; Zhang Y; Wang H; Xiao Y; Wang H; Ge Y; Zou Y; Cui F; Han S; Zhang M; Wang S; Zhu X; Zhang B; Li Z; Ren J; Chen X; Ma R; Zhang L; Guo X; Luo L; Sun X; Yang X
    Vaccine; 2022 Aug; 40(36):5322-5332. PubMed ID: 35931636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults ≥ 60 years of age: Results from a phase III, randomized clinical trial.
    Sanchez L; Nakama T; Nagai H; Matsuoka O; Inoue S; Inoue T; Shrestha A; Pandey A; Chang LJ; De Bruijn I;
    Vaccine; 2023 Apr; 41(15):2553-2561. PubMed ID: 36906404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial.
    Sanchez L; Matsuoka O; Inoue S; Inoue T; Meng Y; Nakama T; Kato K; Pandey A; Chang LJ
    Hum Vaccin Immunother; 2020 Apr; 16(4):858-866. PubMed ID: 31634025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of potential public health impact of a quadrivalent inactivated influenza vaccine in Thailand.
    Kittikraisak W; Chittaganpitch M; Gregory CJ; Laosiritaworn Y; Thantithaveewat T; Dawood FS; Lindblade KA
    Influenza Other Respir Viruses; 2016 May; 10(3):211-9. PubMed ID: 26588892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of a quadrivalent, inactivated, split-virion influenza vaccine (IIV4-W) in healthy people aged 3-60 years: a phase III randomized clinical noninferiority trial.
    Huang X; Fan T; Li L; Nian X; Zhang J; Gao X; Zhao W; Chen W; Zhang Z; Yao Z; Han X; Shi J; Wang Y; Bian H; Shi N; Li X; Duan K; Li G; Yang X
    Hum Vaccin Immunother; 2022 Nov; 18(5):2079924. PubMed ID: 35714276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Time to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled Trial.
    Jain VK; Domachowske JB; Wang L; Ofori-Anyinam O; Rodríguez-Weber MA; Leonardi ML; Klein NP; Schlichter G; Jeanfreau R; Haney BL; Chu L; Harris JS; Sarpong KO; Micucio AC; Soni J; Chandrasekaran V; Li P; Innis BL
    J Pediatric Infect Dis Soc; 2017 Mar; 6(1):9-19. PubMed ID: 28062552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Immunogenicity of a Full-dose, Split-virion, Inactivated, Quadrivalent Influenza Vaccine in Healthy Children 6-35 Months of Age: A Randomized Controlled Clinical Trial.
    Robertson CA; Mercer M; Selmani A; Klein NP; Jeanfreau R; Greenberg DP
    Pediatr Infect Dis J; 2019 Mar; 38(3):323-328. PubMed ID: 30395011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine.
    Levin MJ; Buchwald UK; Gardner J; Martin J; Stek JE; Brown E; Popmihajlov Z
    Vaccine; 2018 Jan; 36(1):179-185. PubMed ID: 28830693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
    Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
    Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in healthy subjects aged 3 to 17 years old: A phase III, open label, single-arm study.
    Chang CY; Cho CY; Lai CC; Lu CY; Chang LY; Hung MC; Huang LM; Wu KG
    Vaccine; 2020 May; 38(22):3839-3846. PubMed ID: 32284272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in children and adolescents: A phase III randomized study.
    Vesikari T; Nauta J; Lapini G; Montomoli E; van de Witte S
    Int J Infect Dis; 2020 Mar; 92():29-37. PubMed ID: 31838217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.